DAIICHI SANKYO ITALIA S.p.A.
Basic information
- Head office
- Chief executive
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| Ranbaxy Laboratories Limited |
Network
History
The origins of Daiichi Sankyo Europe date back to Luitpold-Werk, a pharmaceutical company founded on January 22, 1910 in Munich, Germany.![]()
Since 1962, the company has strengthened its international presence by opening branches in Brazil, Spain, Switzerland, and Italy, and by building a second manufacturing plant in Altkirch, France.![]()
In Europe, the network of scientific drug informants is strengthened by recruiting human resources from Merck Serono in Ireland and Italy.![]()
The company launched a solidarity initiative called "Daiichi Sankyo Children Aid" to support many children in the areas affected by the earthquake in Japan.![]()
At the European Society of Cardiology (ESC) congress, Daiichi Sankyo presented the phase 3 results of the Hokusai-VTE study with edoxaban, an Xa inhibitor.![]()
A month later the company announced the results of the phase 3 ENGAGE AF-TIMI study conducted in patients with non-valvular atrial fibrillation.![]()
At our German manufacturing plant in Pfaffenhofen, near Munich, a new facility for Pharmaceutical Development was inaugurated, employing over 100 staff in a 5,000 square meter environment.![]()
Closing of an exclusive licensing agreement with Esperion Therapeutics for the commercialization of bempedoic acid and the fixed-dose combination of bempedoic acid/ezetimibe.![]()
News
There is no news.